JP6993992B2 - 抗ｐｄ－１抗体、その産生方法及びその使用方法 - Google Patents

抗ｐｄ－１抗体、その産生方法及びその使用方法 Download PDF

Info

Publication number
JP6993992B2
JP6993992B2 JP2018567611A JP2018567611A JP6993992B2 JP 6993992 B2 JP6993992 B2 JP 6993992B2 JP 2018567611 A JP2018567611 A JP 2018567611A JP 2018567611 A JP2018567611 A JP 2018567611A JP 6993992 B2 JP6993992 B2 JP 6993992B2
Authority
JP
Japan
Prior art keywords
antibody
binding
fragment
human
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018567611A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019527543A (ja
JP2019527543A5 (enExample
Inventor
ミクハイローブナ エキモヴァ、ヴィクトリーア
ワレリエヴィチ コルツァーヴィン、ドミトリー
セルゲーブナ チェルニク、ユリア
アレクサンドロヴィチ ネマンキン、ティモフェイ
ウラディミロヴィチ ソロビエフ、ワレリー
コンスタンティノーブナ ウラディミロヴァ、アンナ
アンドレーブナ ブランキナ、イリーナ
ワシリエヴィチ ディデュク、セルゲイ
ウラディミローブナ ゴンチャローヴァ、オルガ
ウラディミローブナ エロショヴァ、アンナ
イウレヴィチ ウスティウゴブ、イアコフ
ウラディミローブナ アルティウコーヴァ、マリナ
ボリショヴィチ ウリティン、アンドレイ
アレクセーヴィチ イヴァノブ、ローマン
ヴァレンティノーヴィチ モロゾフ、ドミトリー
Original Assignee
ジョイント・ストック・カンパニー “バイオキャド”
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジョイント・ストック・カンパニー “バイオキャド” filed Critical ジョイント・ストック・カンパニー “バイオキャド”
Publication of JP2019527543A publication Critical patent/JP2019527543A/ja
Publication of JP2019527543A5 publication Critical patent/JP2019527543A5/ja
Application granted granted Critical
Publication of JP6993992B2 publication Critical patent/JP6993992B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2018567611A 2016-07-13 2017-07-04 抗ｐｄ－１抗体、その産生方法及びその使用方法 Active JP6993992B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2016128487A RU2656181C1 (ru) 2016-07-13 2016-07-13 Анти-pd-1-антитела, способ их получения и способ применения
RU2016128487 2016-07-13
PCT/RU2017/050056 WO2018013017A1 (ru) 2016-07-13 2017-07-04 Анти-pd-1-антитела, способ их получения и способ применения

Publications (3)

Publication Number Publication Date
JP2019527543A JP2019527543A (ja) 2019-10-03
JP2019527543A5 JP2019527543A5 (enExample) 2020-08-13
JP6993992B2 true JP6993992B2 (ja) 2022-01-14

Family

ID=60953256

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018567611A Active JP6993992B2 (ja) 2016-07-13 2017-07-04 抗ｐｄ－１抗体、その産生方法及びその使用方法

Country Status (21)

Country Link
US (1) US11136408B2 (enExample)
EP (1) EP3486257A4 (enExample)
JP (1) JP6993992B2 (enExample)
KR (1) KR102482710B1 (enExample)
CN (1) CN110023335B (enExample)
BR (1) BR112019000436A2 (enExample)
CA (1) CA3021372A1 (enExample)
CL (1) CL2018003407A1 (enExample)
CO (1) CO2019001246A2 (enExample)
CR (1) CR20190009A (enExample)
EC (1) ECSP19010852A (enExample)
JO (1) JOP20190002A1 (enExample)
MA (1) MA44547B1 (enExample)
MX (1) MX2018014937A (enExample)
NI (1) NI201900002A (enExample)
NZ (1) NZ750221A (enExample)
PE (1) PE20190450A1 (enExample)
PH (1) PH12018550179A1 (enExample)
RU (1) RU2656181C1 (enExample)
WO (1) WO2018013017A1 (enExample)
ZA (1) ZA201900792B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA43260A (fr) 2015-11-18 2018-09-26 Merck Sharp & Dohme Liants pd1 et/ou lag3
BR112019013238A2 (pt) 2017-01-20 2020-02-11 Tayu Huaxia Biotech Medical Group Co., Ltd. Anticorpos anti-pd-1 e usos dos mesmos
CN110770345A (zh) 2017-04-14 2020-02-07 托尔奈公司 免疫调节多核苷酸、抗体缀合物及其使用方法
IL271009B2 (en) 2017-06-05 2025-10-01 Janssen Biotech Inc Antibodies that specifically bind PD-1 and methods of use
UY37829A (es) 2017-08-03 2019-01-31 Amgen Inc Muteínas de interleucina 21 y métodos de tratamiento
MA51631A (fr) 2018-01-12 2020-11-18 Amgen Inc Anticorps anti-pd1 et méthodes de traitement
WO2019148410A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1 antibodies
EP3823991A4 (en) * 2018-07-19 2022-08-03 Tayu Huaxia Biotech Medical Group Co., Ltd. ANTI-PD-1 ANTIBODIES, DOSAGE FORMS AND USES THEREOF
CN109652453B (zh) * 2018-12-29 2021-04-06 杭州科兴生物科技有限公司 一种基于pd-1/pdl-1阻断功能及生物效应的抗癌药物快速筛选方法
AU2020281535A1 (en) 2019-05-24 2022-01-27 Merck Patent Gmbh Combination therapies using CDK inhibitors
AU2020290971A1 (en) * 2019-06-14 2021-12-23 Dana-Farber Cancer Institute, Inc. Antibodies against PD-1 and methods of use thereof
CN111420049A (zh) * 2019-08-22 2020-07-17 Biocad股份公司 抗-pd1抗体prolgolimab的水性药物组合物及其应用
RU2753282C2 (ru) * 2019-09-19 2021-08-12 Закрытое Акционерное Общество "Биокад" ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
WO2021174091A1 (en) 2020-02-28 2021-09-02 Tallac Therapeutics, Inc. Transglutaminase-mediated conjugation
JP7512433B2 (ja) 2020-05-26 2024-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｐｄ－１抗体
WO2022118197A1 (en) 2020-12-02 2022-06-09 Pfizer Inc. Time to resolution of axitinib-related adverse events
CN116782937A (zh) * 2020-12-10 2023-09-19 优特力克斯有限公司 抗pd-1抗体及其用途
PE20241732A1 (es) 2021-03-31 2024-08-19 Merus Nv Dominios de union a pd-1 novedosos
TW202304511A (zh) 2021-04-08 2023-02-01 俄羅斯聯邦商拜奧卡德聯合股份公司 使用ｐｄ—１的抗體與化療劑的組合用於治療惡性瘤的方法
WO2023057882A1 (en) 2021-10-05 2023-04-13 Pfizer Inc. Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist
WO2024077069A1 (en) * 2022-10-05 2024-04-11 Chulalongkorn University Monoclonal antibodies against human programmed cell death protein 1 (pd-1)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016068801A1 (en) 2014-10-27 2016-05-06 Agency For Science, Technology And Research Anti-pd-1 antibodies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2161336T4 (en) * 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
NZ582150A (en) * 2007-06-18 2012-08-31 Msd Oss Bv Antibodies to human programmed death receptor pd-1
US8062852B2 (en) * 2007-10-01 2011-11-22 The Children's Hospital And Regional Medical Center Detection and treatment of autoimmune disorders
PT2504364T (pt) * 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
EP2545078A1 (en) * 2010-03-11 2013-01-16 UCB Pharma, S.A. Pd-1 antibody
KR20160044598A (ko) * 2011-03-29 2016-04-25 로슈 글리카트 아게 항체 Fc 변이체
HRP20210122T1 (hr) * 2013-05-02 2021-04-16 Anaptysbio, Inc. Protutijela usmjerena protiv programirane smrti-1 (pd-1)
SG11201601844TA (en) * 2013-09-13 2016-04-28 Beigene Ltd Anti-pd1 antibodies and their use as therapeutics and diagnostics
ES2819451T3 (es) * 2014-08-08 2021-04-16 Univ Leland Stanford Junior Agentes PD-1 de alta afinidad y procedimientos de uso
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016068801A1 (en) 2014-10-27 2016-05-06 Agency For Science, Technology And Research Anti-pd-1 antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
In 2015, pre-clinical trial of the first Russian innovative product for treating skin melanoma will begin，BIOCAD，2014年，[online],[retrieved on 2021-03-02],Retrieved from the Internet: <https://biocad.ru/post/In-2015-pre-clinical-trial-of-the-first-Russian-innovative-product-for-treating-skin-melanoma-will-begin>

Also Published As

Publication number Publication date
ZA201900792B (en) 2020-03-25
CO2019001246A2 (es) 2019-02-19
CA3021372A1 (en) 2018-01-18
MX2018014937A (es) 2019-05-16
NI201900002A (es) 2019-06-11
AU2017297138A1 (en) 2019-02-14
WO2018013017A1 (ru) 2018-01-18
US11136408B2 (en) 2021-10-05
AU2017297138A2 (en) 2019-02-21
EP3486257A1 (en) 2019-05-22
JOP20190002A1 (ar) 2019-01-10
RU2656181C1 (ru) 2018-05-31
JP2019527543A (ja) 2019-10-03
PH12018550179A1 (en) 2019-03-11
AU2017297138A8 (en) 2019-02-28
MA44547A1 (fr) 2020-01-31
BR112019000436A2 (pt) 2019-10-01
KR20190029641A (ko) 2019-03-20
CR20190009A (es) 2019-06-05
CN110023335B (zh) 2024-05-17
US20190127478A1 (en) 2019-05-02
MA44547B1 (fr) 2021-09-30
CL2018003407A1 (es) 2019-03-29
NZ750221A (en) 2022-09-30
EP3486257A4 (en) 2020-03-04
PE20190450A1 (es) 2019-03-29
KR102482710B1 (ko) 2023-01-02
CN110023335A (zh) 2019-07-16
ECSP19010852A (es) 2019-06-30

Similar Documents

Publication Publication Date Title
JP6993992B2 (ja) 抗ｐｄ－１抗体、その産生方法及びその使用方法
JP7488323B2 (ja) 抗ｌａｇ－３抗体および組成物
TWI751981B (zh) 抗pd-1抗體及組成物
TWI859319B (zh) 抗ｃｄ７３抗體及組合物
JP7178999B2 (ja) 抗ｐｄ－１抗体および組成物
TWI752950B (zh) 抗tim-3抗體及組成物
JP7663977B2 (ja) 抗ｐｄ―ｌ１抗体およびその用途
JP2020535839A (ja) Ｃｄ４７およびｐｄ−ｌ１に特異的な抗体
CN112225812B (zh) 结合tfpi的新型抗体以及包含所述抗体的组合物
PT2426150T (pt) Anticorpos anti-nkg2a e utilizações dos mesmos
CN104105708A (zh) PDGF受体β结合多肽
JP2016513088A (ja) 補体関連疾患の予防及び治療のためのｃ５抗体及び方法
KR20170054517A (ko) 항-ｍｅｔ 항체 및 조성물
JP7145895B2 (ja) 組換え二重特異性抗体
WO2021217893A1 (zh) 结合tigit抗原的抗体及其制备方法与应用
KR20210114920A (ko) 인간 및 원숭이 cd38 항원에 특이적으로 결합하는 단일클론항체 및 이의 제조방법과 용도
JP2024509766A (ja) Ｐｄ－ｌ１及びｃｄ４７に対する二重特異性単一ドメイン抗体及びその用途
TW202115123A (zh) 一種抗ｐｄ－ｌ１抗原結合蛋白及其應用
RS55133B1 (sr) Antigen vezujući proteini specifični za p komponentu amiloida seruma
Strohl Therapeutic monoclonal antibodies: past, present, and future
KR102602564B1 (ko) 인터루킨-6의 인간 수용체에 결합가능한 항체 또는 항원 결합성 단편
JP2024512252A (ja) Ｃｄ４７に対する単一ドメイン抗体及びその用途
HK40003751A (en) Anti-pd-1 antibodies, method for producing same and method for using same
HK40003751B (zh) 抗-pd-1 抗体、其生产方法及其使用方法
OA19651A (en) Anti-Pd-1 antibodies, method for producing same and method for using same.

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20191120

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20191121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200706

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200706

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210409

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210421

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210720

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211021

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211122

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211210

R150 Certificate of patent or registration of utility model

Ref document number: 6993992

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250